Evolution of resistance among clinical isolates of Acinetobacter over a 6-year period

被引：46

作者：

Ruiz J. ^{[1
]}

Núñez M.L. ^{[1
]}

Pérez J. ^{[1
]}

Simarro E. ^{[1
]}

Martínez-Campos L. ^{[1
]}

Gómez J. ^{[2
]}

机构：

[1] Laboratory of Microbiology, Hosp. Univ. Virgen de la Arrixaca, Carretera El Palmar-Cartagena

[2] Infectious Diseases Department, Hosp. Univ. Virgen de la Arrixaca, Carretera El Palmar-Cartagena

来源：

European Journal of Clinical Microbiology and Infectious Diseases | 1999年 / 18卷 / 4期

关键词：

Amikacin; Tobramycin; Imipenem; Meropenem; Colistin;

D O I：

10.1007/s100960050280

中图分类号：

学科分类号：

摘要：

The aim of this report was to study the evolution of susceptibilities of 1532 clinical isolates of Acinetobacter recovered over a period of 6 years. The minimal inhibitory concentrations (MICs) of 15 antimicrobial agents were determined for all the isolates. The respective percentages of resistant strains in the years 1991 and 1996 were as follows: ciprofloxacin, 54.4% and 90.4%; tobramycin, 33% and 71.8%; amikacin, 21% and 83.7%; ampicillin plus sulbactam, 65.7% and 84.1%; ceftazidime, 57.4% and 86.8%; ticarcillin, 70% and 89.4%; trimethoprim plus sulfamethoxazole, 41.1% and 88.9%; and imipenem, 1.3% and 80%. The MIC90s of ciprofloxacin, sparfloxacin, biapenem, meropenem, imipenem, cefepime, cefpirome, and rifampicin against 250 imipenem-resistant Acinetobacter strains were > 32, > 32, 128, > 256, 256, > 256, 256, and 16 mg/l, respectively. With serious infections, it was necessary to resort to the use of colistin, the only antibiotic active in vitro.

引用

页码：292 / 295

页数：3

共 15 条

[1]

Bergogne-Bérézin, E., Joly, M.L., Berthelot, G., Fichelle, A., Vieu, J.F., Epidemiologie d'Acinetobacter calcoaceticus (1980) Nouvelle Presse Médicale, 9, pp. 3351-3352

[2]

Harstein, A.I., Rashad, A.L., Liebler, J.M., Actis, L.A., Freeman, J., Rourke, W., Stibolt, T.M., Crosa, J.H., Multiple intensive care unit outbreak of Acinetobacter calcoaceticus subspecies anitratus respiratory infection and colonization associated with contaminated, reusable ventilator circuits and resuscitation bags (1988) American Journal of Medicine, 85, pp. 624-631

[3]

Marcos, M.A., Abdalla, S., Pedraza, F., Andreu, A., Fernández, F., Gómez-Lus, R., Jiménez De Anta, M.T., Vila, J., Epidemiological markers of Acinetobacter baumannii clinical isolates from a spinal cord injury unit (1994) Journal of Hospital Infection, 28, pp. 39-48

[4]

Bouvet, P.J., Jeanjean, S., Delineation of new proteolytic genomic species in the genus Acinetobacter (1989) Research in Microbiology, 140, pp. 291-299

[5]

(1998) Antimicrobial Susceptibility Testing. NCCLS Publication SC3, , NCCLS, Villanova, PA

[6]

Seifert, H., Schulze, A., Baguinski, R., Pulverer, G., Comparison of four different methods in the epidemiological typing of Acinetobacter baumannii (1994) Journal of Clinical Microbiology, 32, pp. 1816-1819

[7]

Go, E.S., Urban, C., Burns, J., Kreiswirth, B., Eisner, W., Mariano, N., Mosinka-Snipas, K., Rahal, J.J., Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam (1994) Lancet, 344, pp. 1329-1332

[8]

Lyytikäinen, O., Köljalg, S., Härmä, M., Vuopio-Varkila, J., Outbreak caused by two multiresistant Acinetobacter baumannii clones in a burns unit: Emergence of resistance to imipenem (1995) Journal of Hospital Infection, 31, pp. 41-54

[9]

Kuah, B.G., Kumarasinghe, G., Doran, J., Chang, H.R., Antimicrobial susceptibilities of clinical isolates of Acinetobacter baumannii from Singapore (1994) Antimicrobial Agents and Chemotherapy, 38, pp. 2502-2503

[10]

Traub, W.H., Spohr, M., Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. Baumannii, A. Haemolyticus, genospecies 3, and genospecies 6) (1989) Antimicrobial Agents and Chemotherapy, 33, pp. 1617-1619

← 1 2 →